The latest information on the medical insurance reimbursement price of Midostaurin

Midostaurin is a multi-target tyrosine kinase inhibitor that has been approved for marketing in Europe, the United States and some Asian countries, and is used to treat a variety of high-risk blood system diseases. Its main indications include FLT3-mutated acute myeloid leukemia (AML), aggressive systemic mastocytosis, systemic mastocytosis with associated hematologic malignancies, and mast cell leukemia. These diseases often progress rapidly and have poor prognosis, and it is difficult for traditional chemotherapy or single targeted therapy to achieve lasting effects.

Midostaurin can play an important role in improving hematological remission rate and prolonging survival through multi-pathway inhibition. In overseas markets, midostaurin is mostly sold in the form of capsules, with a specification of 25 mg, and is often sold according to a course of treatment. Due to its high R&D costs and rare indications, drug pricing is generally on the high side. In Europe and the United States, midostaurin has been included in the medical insurance systems of some countries, and patients can significantly reduce their personal burden through medical insurance reimbursement.

However, in mainland China, the original midostaurin has not yet been officially launched, so it is not included in the national medical insurance catalog. There is no unified medical insurance reimbursement price in the domestic market. Some patients may obtain it through cross-border drug purchase, international medical cooperation channels or imported pharmacies, but the price will be affected by exchange rates, tariffs and transportation costs, and is often higher than most conventional anti-cancer drugs.

In recent years, with the advancement of domestic clinical research and the gradual improvement of rare disease drug policies, midostaurin is expected to be approved for marketing in the near future and entered into the national directory through medical insurance negotiations. Once local supply and medical insurance coverage are achieved, it is expected that its accessibility and patient compliance will significantly improve. For domestic patients who are in urgent need of this drug, they must evaluate the feasibility and risks of purchasing drugs overseas under the guidance of a doctor, and arrange treatment plans reasonably to ensure efficacy and safety.

Reference materials:https://go.drugbank.com/drugs/DB06595